ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Tripathy on Breast Cancer with Bone Metastases

Debu Tripathy, MD
Published: Saturday, Jul 16, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the options available for breast cancer patients with bone metastases at the 28th Annual Miami Breast Cancer Conference.

Tripathy explains that bisphosphonates have been approved to lower skeletal-related events (SREs). These agents are becoming more commonly used. An exciting new agent is denosumab (Xgeva); Tripathy explains that this drug has shown more benefits and advantages, compared to other approved drugs, for the treatment of SREs.
Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the options available for breast cancer patients with bone metastases at the 28th Annual Miami Breast Cancer Conference.

Tripathy explains that bisphosphonates have been approved to lower skeletal-related events (SREs). These agents are becoming more commonly used. An exciting new agent is denosumab (Xgeva); Tripathy explains that this drug has shown more benefits and advantages, compared to other approved drugs, for the treatment of SREs.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x